Interim phase 3 data show a 58% reduction in the risk of metastasis or death with the addition of darolutamide to ADT + radiation.
|Videos|December 23, 2020
Dr. Adam J. Gadzinski describes the emergence of precision medicine in prostate cancer
Author(s)Urology Times staff
Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.
Advertisement
In this video, Adam J. Gadzinski, MD, MS, highlights how precision medicine in prostate cancer was a key topic at the 2020 Society of Urologic Oncology Annual Meeting and marks the next great leap forward in the field. Gadzinski is an acting instructor of urologic oncology at the Urology Clinic at the University of Washington Medical Center.
Advertisement
Related to this article
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5